News & Updates
Filter by Specialty:
Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.
Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
22 Mar 2022
Fulvestrant–sapanisertib combo shows modest benefit in advanced, metastatic breast cancer
Treatment with the combination of fulvestrant plus sapanisertib yields a numerical increase in progression-free survival in patients with ER-positive, HER2-negative advanced or metastatic breast cancer as compared with the use of fulvestrant alone, according to the results of a phase II trial. However, the combination is associated with increased toxicity.
Fulvestrant–sapanisertib combo shows modest benefit in advanced, metastatic breast cancer
22 Mar 2022
Respiratory-gated PET-CT improves liver tumour imaging
A prospective clinical study conducted by the Hong Kong Baptist Hospital in collaboration with the Hong Kong Polytechnic University has demonstrated the feasibility of implementing respiratory-gated PET-CT for liver malignancies with improved image quality compared with ungated scans.
Respiratory-gated PET-CT improves liver tumour imaging
17 Mar 2022
Olaparib-abiraterone combo improves PFS in mCRPC
The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.
Olaparib-abiraterone combo improves PFS in mCRPC
16 Mar 2022
Transgender people less likely to undergo cancer screening
Despite being at increased risk for breast and cervical cancer, transgender people experience inequalities in the uptake of routine cancer screening, a study has found.
